A new global strategy for 3-vessel disease from SYNTAX II: iFR/FFR and IVUS-guided PCR and new-generation DES

Summary

The early, 30-day outcomes, from the SYNTAX II trial are in and P. Serruys is here to challenge us with these early results. How do we “open the dialogue” on this new global strategy for treating three-vessel disease? What are the questions we need to ask both surgeon and patient? What is the role of imaging? Of iFR/FFR assessment, of IVUS-guided percutaneous coronary revascularisation?  And what about newer-generation DES?

Let P. Serruys lead us through, step-by-step…